Changeflow GovPing Healthcare VYLOY Patent Extension Application Comment Period
Routine Consultation Added Consultation

VYLOY Patent Extension Application Comment Period

Email

Summary

FDA opened a 60-day public comment period on a patent term extension application for VYLOY, a drug product. Commenters may submit feedback through regulations.gov regarding this application.

What changed

This is a comment submission portal on regulations.gov for FDA-2025-E-0868-0006, concerning a patent term extension application for the drug product VYLOY. The FDA is seeking public input before taking action on the extension request. The specific details of the patent extension (original expiration date, extension duration requested, regulatory basis) are not contained in this form page but would be in the underlying application documents.

Pharmaceutical companies and patent holders should review whether they have relevant information to submit, including prior art, competing applications, or other grounds for comment. The 60-day comment window provides an opportunity for competitors, researchers, or other stakeholders to formally object or provide input before FDA makes a determination on the extension.

Archived snapshot

Apr 3, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Write a Comment

Commenter's Checklist
Public Comments on Federal Regulations

Comment *

5000

What is your comment about?

Attach Files

You can attach up to 20 files, but each file cannot exceed 10MB. Valid file types include: bmp, docx, gif, jpg, jpeg, pdf, png, pptx, rtf, sgml, tif, tiff, txt, wpd, xlsx, xml. Drop files here or Browse...

Email Address

Opt to receive email confirmation of submission and tracking number?
If you choose to identify as Anonymous, the option to receive an email confirmation will not be displayed. (We will never post the email address entered in the field above on Regulations.gov nor share it with anyone else.)

Tell us about yourself! I am... *

(Select an identity below)

An Individual

Yourself or another person whom
you represent with their consent

An Organization

A company, organization,
or government agency

Anonymous

A person who does not want their name
associated with the comment

Note: If you choose to identify as Anonymous, the option to enter your email address for submission confirmation is not available.

reCAPTCHA *

Solve with 2Captcha Do not submit personally identifiable information through this form. Any personally identifiable information (e.g., name, address, phone number) included in the comment form or in an attachment may be publicly disclosed in a docket or on the Internet (via Regulations.gov, a federal agency website, or a third-party, non-government website with access to publicly-disclosed data on Regulations.gov). By submitting a comment, you agree to the terms of participation and privacy notice.

Submit Comment

Please see the Privacy Notice and User Notice regarding comment submission.

Any information (e.g., personal or contact) you provide on this comment form or in an attachment may be publicly disclosed and searchable on the Internet and in a paper docket and will be provided to the Department or Agency issuing the notice. To view any additional information for submitting comments, such as anonymous or sensitive submissions, refer to the Privacy Notice and User Notice, the Federal Register notice on which you are commenting, and the Web site of the Department or Agency.

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
FDA
Instrument
Consultation
Legal weight
Non-binding
Stage
Consultation
Change scope
Minor
Document ID
FDA-2025-E-0868-0006
Docket
FDA-2025-E-0868-0006

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Patent Extensions
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property Drug Approval

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.